AUTH:"Tausch E" - Search results

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivchev L, Niemann CU, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, [...] Fischer K

Blood, 144(18):1924-1935, 01 Oct 2024

Cited by: 2 articles | PMID: 39082668 | PMCID: PMC11551846

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

The NOTCH1 and miR-34a signaling network is affected by <i>TP53</i> alterations in CLL.

Ehrmann AS, Zadro A, Tausch E, Schneider C, Stilgenbauer S, Mertens D

Leuk Lymphoma, 1-13, 19 Aug 2024

Cited by: 0 articles | PMID: 39161195

Add to export list

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, Goede V, von Tresckow J, Langerbeins P, Fink AM, Huber H, Tausch E, Schneider C, Wendtner CM, Ritgen M, Dreyling M, Müller L, Jacobasch L, Heinz WJ, [...] Al-Sawaf O

J Clin Oncol, JCO2401192, 23 Aug 2024

Cited by: 0 articles | PMID: 39213466

Add to export list

Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.

Enzenmüller S, Niedermayer A, Seyfried F, Muench V, Tews D, Rupp U, Tausch E, Groß A, Fischer-Posovszky P, Walther P, Stilgenbauer S, Kestler HA, Debatin KM, Meyer LH

Cell Death Dis, 15(7):475, 03 Jul 2024

Cited by: 1 article | PMID: 38961053 | PMCID: PMC11222427

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, [...] Cramer P

Blood, 144(3):272-282, 01 Jul 2024

Cited by: 0 articles | PMID: 38620072

Add to export list

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.

Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter M, Niemann CU, da Cunha-Bang C, Kater A, Dubois J, Gregor M, Staber PB, Tausch E, [...] Hallek M

Blood, 143(25):2588-2598, 01 Jun 2024

Cited by: 2 articles | PMID: 38620092

Add to export list

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kater AP, van der Spek E, Niemann CU, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Fischer K, Hallek M, Eichhorst B

Am J Hematol, 99(8):1620-1623, 17 May 2024

Cited by: 0 articles | PMID: 38757754

Add to export list

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, [...] Eichhorst B

Lancet Oncol, 25(6):744-759, 01 Jun 2024

Cited by: 1 article | PMID: 38821083

Add to export list

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.

Malcikova J, Pavlova S, Baliakas P, Chatzikonstantinou T, Tausch E, Catherwood M, Rossi D, Soussi T, Tichy B, Kater AP, Niemann CU, Davi F, Gaidano G, Stilgenbauer S, Rosenquist R, Stamatopoulos K, Ghia P, Pospisilova S

Leukemia, 38(7):1455-1468, 16 May 2024

Cited by: 3 articles | PMID: 38755420 | PMCID: PMC11217004

Add to export list Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.

Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuß A, Vehling-Kaiser U, Koenigsmann M, Tausch E, Schneider C, Stilgenbauer S, Illmer T, Schlag R, Dörfel S, Gaska T, Kiehl M, Müller-Hagen S, Moorahrend E, Linde H, [...] Fink AM

Eur J Haematol, 113(2):235-241, 01 May 2024

Cited by: 0 articles | PMID: 38693677

Add to export list

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, [...] Seymour JF

Blood Adv, 8(8):1992-2004, 01 Apr 2024

Cited by: 2 articles | PMID: 38290108 | PMCID: PMC11024923

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M

Am J Hematol, 99(6):1192-1195, 05 Apr 2024

Cited by: 0 articles | PMID: 38578022

Add to export list

Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms - a practical guide to WHO HAEM5.

Tausch E, López C, Stilgenbauer S, Siebert R

Med Genet, 36(1):47-57, 06 Mar 2024

Cited by: 0 articles | PMID: 38835970 | PMCID: PMC11006374

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, [...] Eichhorst B

Nat Med, 30(1):240-248, 09 Dec 2023

Cited by: 3 articles | PMID: 38071379 | PMCID: PMC10803258

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, [...] Fischer K

Nat Commun, 14(1):6724, 23 Oct 2023

Cited by: 2 articles | PMID: 37872229 | PMCID: PMC10593794

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.

Qi J, Endres S, Yosifov DY, Tausch E, Dheenadayalan RP, Gao X, Müller A, Schneider C, Mertens D, Gierschik P, Wist M, Jebaraj BMC, Stilgenbauer S

Blood Adv, 7(19):5698-5702, 01 Oct 2023

Cited by: 6 articles | PMID: 36661329 | PMCID: PMC10539862

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, [...] Stilgenbauer S

Blood, 142(11):961-972, 01 Sep 2023

Cited by: 9 articles | PMID: 37363867

Add to export list

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS

Yosifov D, von Tresckow J, Giza A, Robrecht S, Schneider C, Jebaraj B, Mertens D, Ritgen M, Schilhabel A, Kreuzer K, Maria Fink A, Al-Sawaf O, Langerbeins P, Fischer K, Eichhorst B, Hallek M, Döhner H, Stilgenbauer S, Cramer P, Tausch E

Hemasphere, 7(suppl ), 01 Aug 2023

Cited by: 0 articles | PMCID: PMC10429433

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS

Qi J, Wist M, Tausch E, Yordanov Yosifov D, Schade A, Gao X, Priyadharshini Dheenadayalan R, Schneider C, Endres S, Mertens D, Gierschik P, Stilgenbauer S, Michael Chelliah Jebaraj B

Hemasphere, 7(suppl ), 01 Aug 2023

Cited by: 0 articles | PMCID: PMC10429041

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang Y, Fink A, Tausch E, Schneider C, Ritgen M, Kreuzer K, Sivcheva L, Niemann C, Schwarer A, Loscertales Pueyo J, Weinkove R, Strumberg D, Kilfoyle A, Runkel E, Eichhorst B, [...] Fischer K

Hemasphere, 7(suppl ), 01 Aug 2023

Cited by: 0 articles | PMCID: PMC10428511

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, [...] Kater AP

Blood, 142(5):446-459, 01 Aug 2023

Cited by: 9 articles | PMID: 37172204

Add to export list

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

Simon F, Ligtvoet R, Noesslinger T, Bohn J, Von Tresckow J, Liersch R, Gaska T, Jentsch-Ullrich K, Koenigsmann M, Wolff T, Schwaner I, Wolf D, Schneider C, Tausch E, Stilgenbauer S, Kreuzer K, Robrecht S, Fink A, Fürstenau M, [...] Eichhorst B

Hemasphere, 7(suppl ), 01 Aug 2023

Cited by: 0 articles | PMCID: PMC10429528

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

Langerbeins P, Robrecht S, Nieper P, Cramer P, Fürstenau M, Al-Sawaf O, Fink A, Kreuzer K, Vehling-Kaiser U, Tausch E, Schneider C, Müller L, Eckart M, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, [...] Hallek M

Hemasphere, 7(suppl ), 01 Aug 2023

Cited by: 0 articles | PMCID: PMC10428394

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, [...] and Cancer Trials Ireland

N Engl J Med, 388(19):1739-1754, 01 May 2023

Cited by: 54 articles | PMID: 37163621

Add to export list

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, [...] Fischer K

Nat Commun, 14(1):2147, 18 Apr 2023

Cited by: 18 articles | PMID: 37072421 | PMCID: PMC10113251

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

The NOTCH1 and miR-34a signaling network is affected by <i>TP53</i> alterations in CLL.

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.

Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms - a practical guide to WHO HAEM5.

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS

P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Partnerships & funding